Real-Life Effectiveness and Safety of Sofosbuvir-Based Therapy in Genotype 2 Chronic Hepatitis C Patients in South Korea, with Emphasis on the Ribavirin Dose
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: Sofosbuvir (SOF)-based therapy has been used in Korean patients with chronic hepatitis C virus (HCV) infection since January 2016. This study aimed to investigate the real-life effectiveness and safety of SOF-based therapy in genotype 2 HCV infection. Methods: From January to December 2016, 458 genotype 2 HCV-infected patients who received ≥1 dose of SOF-based therapy were consecutively enrolled in seven tertiary hospitals. Sustained virologic response (SVR) rates and safety were determined by intention- to-treat (ITT) and per-protocol (PP) analyses. Results: The mean age of the patients was 61.0 years; 183 (40%) were male, and 13.1% showed a high viral load (>6,000,000 IU/ mL). Among the 378 treatment-naïve patients, the SVR rates were 94.2% (ITT) and 96.7% (PP). Among the 80 treatmentexperienced patients, the SVR rates were 96.3% (ITT) and 98.7% (PP). Patients with a relatively high fibrosis-4 index score (>3.25) had similar SVR rates to those with a relatively low score (p=0.756). A total of 314 patients (68.6%) were treated with a reduced ribavirin dose at the prescriber’s discretion, but they showed similar SVR rates to those treated with the weight-based dose (ITT: 95.5% and 92.3%, PP: 97.4% and 96.3%, respectively). Adverse events were observed in 191 patients (41.7%), including 86 (18.8%) with anemia, but only one (0.2%) discontinued antiviral therapy due to nausea. Conclusions: SOF-based therapy showed high real-life efficacy and tolerability in Korean patients with genotype 2 chronic HCV infection, regardless of previous antiviral treatment experience and fibrosis score. A reduced ribavirin dose can be considered in this patient cohort.
Abstract
Background/Aims: Sofosbuvir (SOF)-based therapy has been used in Korean patients with chronic hepatitis C virus (HCV) infection since January 2016. This study aimed to investigate the real-life effectiveness and safety of SOF-based therapy in genotype 2 HCV infection. Methods: From January to December 2016, 458 genotype 2 HCV-infected patients who received ≥1 dose of SOF-based therapy were consecutively enrolled in seven tertiary hospitals. Sustained virologic response (SVR) rates and safety were determined by intention- to-treat (ITT) and per-protocol (PP) analyses. Results: The mean age of the patients was 61.0 years; 183 (40%) were male, and 13.1% showed a high viral load (>6,000,000 IU/ mL). Among the 378 treatment-naïve patients, the SVR rates were 94.2% (ITT) and 96.7% (PP). Among the 80 treatmentexperienced patients, the SVR rates were 96.3% (ITT) and 98.7% (PP). Patients with a relatively high fibrosis-4 index score (>3.25) had similar SVR rates to those with a relatively low score (p=0.756). A total of 314 patients (68.6%) were treated with a reduced ribavirin dose at the prescriber’s discretion, but they showed similar SVR rates to those treated with the weight-based dose (ITT: 95.5% and 92.3%, PP: 97.4% and 96.3%, respectively). Adverse events were observed in 191 patients (41.7%), including 86 (18.8%) with anemia, but only one (0.2%) discontinued antiviral therapy due to nausea. Conclusions: SOF-based therapy showed high real-life efficacy and tolerability in Korean patients with genotype 2 chronic HCV infection, regardless of previous antiviral treatment experience and fibrosis score. A reduced ribavirin dose can be considered in this patient cohort.
참고문헌 (31)
- Mohd Hanafiah K, "Global epidemiology of hepatitis C virus infection : new estimates of age-specific antibody to HCV seroprevalence", Hepatology, 57, pp.1333~1342 (2013)
- Stanaway JD, "The global burden of viral hepatitis from 1990 to 2013 : findings from the Global Burden of Disease Study 2013", Lancet, 388, pp.1081~1088 (2016)
- Kim DY, "A nationwide seroepidemiology of hepatitis C virus infection in South Korea", Liver Int, 33, pp.586~594 (2013)
- Sang Soo Lee, "Type and cause of liver disease in Korea: single-center experience, 2005-2010", Clinical and Molecular Hepatology, 18(3), pp.309~315 (2012), 대한간학회[DOI]
- Seong MH, "Clinical and epidemiological features of hepatitis C virus infection in South Korea : a prospective, multicenter cohort study", J Med Virol, 85, pp.1724~1733 (2013)
- The Korean Association for the Study of the Liver, "KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications", Clinical and Molecular Hepatology, 24(3), pp.169~229 (2018), 대한간학회
- Toyoda H, "Efficacy and safety of glecaprevir", pibrentasvir in Japanese patients with chronic genotype 2hepatitis C virus infection, 2018, pp.67, 505~513
- Asselah T, "Efficacy of glecaprevir", pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis, 2018, pp.16, 417~426
- Jacobson IM, "Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection : 2 phase 3 randomized trials", Gastroenterology, 153, pp.113~122 (2017)
- Bourlière M, "Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection", N Engl J Med, 376, pp.2134~2146 (2017)
- Lawitz E, "Sofosbuvir for previously untreated chronic hepatitis C infection", N Engl J Med, 368, pp.1878~1887 (2013)
- Ahn SH, "A phase 3b study of sofosbuvir plus ribavirin in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 2 hepatitis C virus", J Viral Hepat, 23, pp.358~365 (2016)
- Omata M, "Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection : an open-label, phase 3 trial", J Viral Hepat, 21, pp.762~768 (2014)
- Jacobson IM, "Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options", N Engl J Med, 368, pp.1867~1877 (2013)
- Zeuzem S, "Sofosbuvir and ribavirin in HCV genotypes 2 and 3", N Engl J Med, 370, pp.1993~2001 (2014)
- 김주승, "The Impact of Inosine Triphosphatase Variants on Hemoglobin Level and Sustained Virologic Response of Chronic Hepatitis C in Korean", Journal of Korean Medical Science, 28(8), pp.1213~1219 (2013), 대한의학회
- Kurosaki M, "Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin", Antivir Ther, 16, pp.685~694 (2011)
- 권정현, "Assessment of the Efficacy of Reducing Peginterferon Alfa-2a and Ribavirin Dose on Virologic Response in Koreans with Chronic Hepatitis C", The Korean Journal of Internal Medicine, 24(3), pp.203~211 (2009), 대한내과학회
- 이혁, "우리나라 만성 C형간염의 초치료를 위한 페그인터페론과 리바비린 병합요법", Clinical and Molecular Hepatology, 12(2006), pp.31~40 (2006), 대한간학회
- Suk KT, "Revision and update on clinical practice guideline for liver cirrhosis", Korean J Hepatol, 18, pp.1~21 (2012)
- Sterling RK, "Development of a simple noninvasive index to predict significant fibrosis in patients with HIV", HCV coinfection, 2006, pp.43, 1317~1325
- Reddy KR, "All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice : observations through HCV-TARGET database", Aliment Pharmacol Ther, 45, pp.115~126 (2017)
- Akahane T, "Real-world efficacy and safety of sofosbuvir + ribavirin for hepatitis C genotype 2 : a nationwide multicenter study by the Japanese Red Cross Liver Study Group", Hepatol Res, 49, pp.264~270 (2019)
- Young Min Kim, "Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study", Clinical and Molecular Hepatology, 24(3), pp.311~318 (2018), 대한간학회
- Ogawa E, "Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis", Antiviral Res, 136, pp.37~44 (2016)
- European Association for the Study of the Liver, "EASL recommendations on treatment of hepatitis C 2018", J Hepatol, 69, pp.461~511 (2018)
- Morio K, "Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis C", J Med Virol, 90, pp.1834~1840 (2018)
- Korean Association for the Study of the Liver, "KASL clinical practice guidelines : management of hepatitis C", Clin Mol Hepatol, 22, pp.76~139 (2016)
- Kozuka R, "Correlation between polymorphism in the inosine triphosphatase and the reductions in hemoglobin concentration and ribavirin dose during sofosbuvir and ribavirin therapy", J Gastroenterol Hepatol, 32, pp.1495~1502 (2017)
- Hu KQ, "Impact of Hispanic or Asian ethnicity on the treatment outcomes of chronic hepatitis C : results from the WIN-R trial", J Clin Gastroenterol, 45, pp.720~726 (2011)
- Borroni G, "Low glomerular filtration rate is a risk factor for ribavirin-associated anaemia in old patients with chronic hepatitis C", J Viral Hepat, 20, pp.e90~e95 (2013)